| Rank |
Status |
Study |
| 1 |
Recruiting
|
Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis
| Conditions: |
Rhabdomyolysis; Acute Kidney Failure |
| Intervention: |
Biological: Plasma NGAL level |
| Outcome Measures: |
Plasma NGAL level; Delay between initiation of treatment and beginning of acute renal failure; Delay between cause and treatment; Need for extracorporeal blood purification; Patient admitted to ICU?; Length of hospitalization; Patient deceased during hospitalization |
|
| 2 |
Recruiting
|
Myoglobin Removal by High Cut-off CVVHD
| Conditions: |
Rhabdomyolysis; Renal Failure |
| Interventions: |
Device: septeX; Device: HF CVVH |
| Outcome Measures: |
Myoglobin plasma level; eGFR; Duration of hospital stay (days)and Duration of ICU stay (days); Duration of dialysis dependence (days); Diuresis / oliguria (<0.5 ml/kg/12h)/ anuria; patient survival |
|
| 3 |
Unknown †
|
Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients
| Conditions: |
Rhabdomyolysis; Myopathy; Acute Renal Failure; Neuroleptic Malignant Syndrome |
| Intervention: |
|
| Outcome Measure: |
|
|
| 4 |
Recruiting
|
Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis
| Condition: |
Rhabdomyolysis |
| Interventions: |
Device: CytoSorb Device; Procedure: CVVH |
| Outcome Measures: |
Efficacy of device as measured by change in myoglobin; Assessment of serious device or procedure-related adverse events |
|
| 5 |
Recruiting
|
Nutritional Prevention of Exertional Muscle Dysfunction
| Conditions: |
Muscle Dysfunction; Exertional Rhabdomyolysis; Muscle Strength |
| Interventions: |
Dietary Supplement: Choline; Dietary Supplement: Placebo |
| Outcome Measure: |
Creatine Kinase (CK) activity |
|
| 6 |
Recruiting
|
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
| Conditions: |
Stroke; Rhabdomyolysis; Jaundice |
| Interventions: |
Drug: Lovastatin; Other: Placebo |
| Outcome Measures: |
Increase in Liver Function Tests (LFTs); Increase in Creatine Kinase (CK); Score on NIH Stroke Scale; Barthel Index Score; Modified Rankin scores |
|
| 7 |
Unknown †
|
The Association of Genetic Polymorphisms With Statin-Induced Myopathy.
| Conditions: |
Rhabdomyolysis; Myopathy |
| Intervention: |
Genetic: DNA |
| Outcome Measures: |
genotype of specific genes; single nucleotide polymorphism |
|
| 8 |
Unknown †
|
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
| Conditions: |
Hyperlipidemia; Hypercholesterolemia |
| Interventions: |
Drug: ezetimibe; Drug: niacin; Drug: colestipol |
| Outcome Measures: |
To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. The patient’s cardiovascular risks are assessed to determine i; . Secondary measures examine the safety issues with liver function test (LFT) monitoring and Rhabdomyolysis. High-density lipoproteins (HDL) elevations are monitored between the three groups to determine efficacy as a secondary outcome. |
|
| 9 |
Recruiting
|
Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria
| Condition: |
Malaria |
| Interventions: |
Drug: Paracetamol; Drug: No Paracetamol |
| Outcome Measures: |
Effect of paracetamol concentrations; Compare treatment arm with control arm with respect to duration of Acute Kidney Injury (AKI) and development of AKI.; Oxidative stress assessed by measuring F2-isoprostanes (F2-IsoPs); Assessment of Blackwater fever; Mortality trends; Intravascular Haemolysis; Fever clearance time; Parasite clearance time; Parasite sequestration; Assessment of Acute Kidney Injury; Creatinine clearance; Safety assessment |
|
| 10 |
Recruiting
|
Statins Evaluation in Coronary Procedures and Revascularization Trial
| Condition: |
Acute Coronary Syndrome |
| Interventions: |
Drug: Atorvastatin; Drug: Placebo |
| Outcome Measures: |
Major Cardiovascular Events (MACE); Cardiovascular Mortality; Revascularization of the Target Lesion; Non-fatal Myocardial Infarction; Stent Thrombosis; Stroke; Rhabdomyolysis; Bleeding episode; All-cause mortality; Recurrent ischemia leading to urgent revascularization |
|
| 11 |
Not yet recruiting
|
Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging
| Condition: |
Intracranial Arterial Stenosis |
| Intervention: |
Drug: Rosuvastatin |
| Outcome Measures: |
The change in the percentage of volume of MCA atherosclerosis plaque after 2 years treatment of Rosuvastatin 10-20mg; The change in Percentage of plaque volume of M1segment plaque; The change in Percentage of lumen volume; The change in percentage of lipid rich necrotic core; Recurrency of stroke or TIA; The change of percentage in LDL-C from baseline; The change in HDL-C level from baseline; To explore the relationship between the change of plaque volumn and morphology and the change in LDL-C, HDL-C and Hs-CRP level; safety-Rhabdomyolysis，Hepatonecrosis; The change in percentage of thickness of fibrous cap; The change in percentage of intraplaque hemorrhage; The change in hsCRP level from baseline; 2.Severe bleeding incidence (GUSTO definition), including fatal bleeding and symptomatic intracranial hemorrhage; Incidence symptomatic and asymptomatic intracranial hemorrhagic events at 3 months; Moderate bleeding (GUSTO definition); Intracranial hemorrhage; Total mortality; AEs/SAEs reported by the investigators |
|
| 12 |
Not yet recruiting
|
The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients
| Conditions: |
Dyslipidemia; Transplants |
| Intervention: |
Drug: Ezetimibe |
| Outcome Measures: |
Decrease of LDL cholesterol concentration.; Change in oxidative markers |
|
| 13 |
Unknown †
|
West Indies-French Guiana Dengue Study
| Conditions: |
Fever; Dengue |
| Interventions: |
Other: biological sample collection; Other: quality of life questionnaire EuroQol® |
| Outcome Measures: |
Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.; Onset of dengue hemorrhagic fever (WHO criteria). Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms. |
|
| 14 |
Unknown †
|
Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation
| Condition: |
Burns |
| Intervention: |
|
| Outcome Measure: |
|
|
